Summary of systematic review outcomes
| Study . | Thrombosis . | Transfusion . | No. of Trials . | No. of Patients . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | No. of Trials . | No. of Patients . | |||
| Seidenfeld et al4 | ||||||||||||
| EPO v DAR | 58/948 (DAR) | 66/931 (EPO) | 0.86 | 0.61 to 1.21 | 3 | 189 | 252/1169 | 198/989 | 1.10 | 0.93 to 1.29 | 6 | 2158 |
| EPO v control | 218/3355 | 112/2737 | 1.69 | 1.36 to 2.10 | 30 | 6092 | 864/2859 | 1110/2351 | 0.63 | 0.59 to 0.67 | 34 | 5210 |
| DAR v control | 7/155 | 5/159 | 1.44 | 0.47 to 4.43 | 1 | 314 | 165/566 | 196/384 | 0.61 | 0.52 to 0.72 | 4 | 950 |
| Bohlius et al3,39 | 229/3,728 | 118/3,041 | 1.67 | 1.35 to 2.06 | 35 | 6,769 | 1118/3,637 | 1385/2,873 | 0.64 | 0.60 to 0.68 | 42 | 6,510 |
| Quirt et al6 | DVT-2 studies report: Schwartzberg (2004): EPO, n = 1/155, DAR, n = 1/157; Rosenzweig (2004): EPO, n = 4/14; pulmonary embolism, 2 studies report: Schwartzberg (2004): EPO, n = 1/155; DAR, n = 0/157; Rosenzweig (2004): EPO, n = 2/14 | Rosenzweig (2004): control n = NA for both DVT + PE | NR | 385/1,750 | 588/1,419 | 0.52 | 0.46 to 0.60 | 30 trials (33 comparisons) | 3,169 | |||
| Shehata et al7 | Thrombosis: EPOα or β frequency, range, 3%–7%, control frequency, range, 2%–6%; DARα, not reported, 5 trials | NR | EPO α or β absolute risk reduction ranged from 15%−24%, 6 trials; DARα absolute risk reduction ranged from 17%−30%, 2 trials | |||||||||
| Wilson et al5 | Study 1: vascular: BP,VT,PE,CVA 20/180; study 2: thrombic events 4/14; study 3: thrombic events 7/156 | Study 1: vascular 9/171; study 2: NR; study 3: thrombic events 5/158 | NR | 834/2,637 | 988/1,976 | 0.63 | 0.58 to 67 | 35 | 4,613 | |||
| . | Overall Survival . | Tumor Response . | ||||||||||
| Events: ESA Arms . | Control Arms . | Hazard Ratio . | 95% CI . | No. of Trials . | No. of Patients . | Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | No. of Trials . | No. of Patients . | |
| Seidenfeld et al4 | ||||||||||||
| EPO v DAR | 29/180 | 23/178 | 1.25 | 0.76 to 2.07 | 1 | 358 | ||||||
| EPO v control | 1,008/3,825 | 830/3,093 | 1.11 | 1.00 to 1.22 | 35 | 6,918 | 216/344 | 211/344 | 1.00 | 0.92 to 1.10 | 5 | 688 |
| DAR v control | 181/583 | 183/390 | 0.96 | 0.78 to 1.17 | 4 | 973 | ||||||
| Bohlius et al3,39 | NR | NR | 1.08 | 0.99 to 1.18 | 42 | 8,167 | 413/1509 | 324/1,324 | 1.12 | 1.01 to 1.23 | 13 | 2,833 |
| Quirt et al6 | NR | NR | NR | NR | NR | |||||||
| Shehata et al7 | Littlewood et al (2001) report EPOα = 60% for patients with solid tumors and hematologic malignancies, control = 40% (P = .13); Osterborg et al (2005) report EPOα = 65%, control = 63%, HR = 1.04 (0.80–1.36); DARα HR = 0.95, P = .619, 4 trials | |||||||||||
| Wilson et al5 | 675/2,986 deaths | 545/2,322 | 1.03 | 0.92 to 1.16 | 28 | 5,308 | 169/723 | 91/537 | 1.31 | 1.08 to 1.60 | 8 | 1,260 |
| Study . | Thrombosis . | Transfusion . | No. of Trials . | No. of Patients . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | No. of Trials . | No. of Patients . | |||
| Seidenfeld et al4 | ||||||||||||
| EPO v DAR | 58/948 (DAR) | 66/931 (EPO) | 0.86 | 0.61 to 1.21 | 3 | 189 | 252/1169 | 198/989 | 1.10 | 0.93 to 1.29 | 6 | 2158 |
| EPO v control | 218/3355 | 112/2737 | 1.69 | 1.36 to 2.10 | 30 | 6092 | 864/2859 | 1110/2351 | 0.63 | 0.59 to 0.67 | 34 | 5210 |
| DAR v control | 7/155 | 5/159 | 1.44 | 0.47 to 4.43 | 1 | 314 | 165/566 | 196/384 | 0.61 | 0.52 to 0.72 | 4 | 950 |
| Bohlius et al3,39 | 229/3,728 | 118/3,041 | 1.67 | 1.35 to 2.06 | 35 | 6,769 | 1118/3,637 | 1385/2,873 | 0.64 | 0.60 to 0.68 | 42 | 6,510 |
| Quirt et al6 | DVT-2 studies report: Schwartzberg (2004): EPO, n = 1/155, DAR, n = 1/157; Rosenzweig (2004): EPO, n = 4/14; pulmonary embolism, 2 studies report: Schwartzberg (2004): EPO, n = 1/155; DAR, n = 0/157; Rosenzweig (2004): EPO, n = 2/14 | Rosenzweig (2004): control n = NA for both DVT + PE | NR | 385/1,750 | 588/1,419 | 0.52 | 0.46 to 0.60 | 30 trials (33 comparisons) | 3,169 | |||
| Shehata et al7 | Thrombosis: EPOα or β frequency, range, 3%–7%, control frequency, range, 2%–6%; DARα, not reported, 5 trials | NR | EPO α or β absolute risk reduction ranged from 15%−24%, 6 trials; DARα absolute risk reduction ranged from 17%−30%, 2 trials | |||||||||
| Wilson et al5 | Study 1: vascular: BP,VT,PE,CVA 20/180; study 2: thrombic events 4/14; study 3: thrombic events 7/156 | Study 1: vascular 9/171; study 2: NR; study 3: thrombic events 5/158 | NR | 834/2,637 | 988/1,976 | 0.63 | 0.58 to 67 | 35 | 4,613 | |||
| . | Overall Survival . | Tumor Response . | ||||||||||
| Events: ESA Arms . | Control Arms . | Hazard Ratio . | 95% CI . | No. of Trials . | No. of Patients . | Events: ESA Arms . | Control Arms . | Relative Risk . | 95% CI . | No. of Trials . | No. of Patients . | |
| Seidenfeld et al4 | ||||||||||||
| EPO v DAR | 29/180 | 23/178 | 1.25 | 0.76 to 2.07 | 1 | 358 | ||||||
| EPO v control | 1,008/3,825 | 830/3,093 | 1.11 | 1.00 to 1.22 | 35 | 6,918 | 216/344 | 211/344 | 1.00 | 0.92 to 1.10 | 5 | 688 |
| DAR v control | 181/583 | 183/390 | 0.96 | 0.78 to 1.17 | 4 | 973 | ||||||
| Bohlius et al3,39 | NR | NR | 1.08 | 0.99 to 1.18 | 42 | 8,167 | 413/1509 | 324/1,324 | 1.12 | 1.01 to 1.23 | 13 | 2,833 |
| Quirt et al6 | NR | NR | NR | NR | NR | |||||||
| Shehata et al7 | Littlewood et al (2001) report EPOα = 60% for patients with solid tumors and hematologic malignancies, control = 40% (P = .13); Osterborg et al (2005) report EPOα = 65%, control = 63%, HR = 1.04 (0.80–1.36); DARα HR = 0.95, P = .619, 4 trials | |||||||||||
| Wilson et al5 | 675/2,986 deaths | 545/2,322 | 1.03 | 0.92 to 1.16 | 28 | 5,308 | 169/723 | 91/537 | 1.31 | 1.08 to 1.60 | 8 | 1,260 |
Abbreviations: EPO-α, epoetin α; EPO-β, epoetin β; DAR, darbepoetin; NA, not applicable; NR, not reported.